Patents by Inventor Inga Cikotiene

Inga Cikotiene has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240102003
    Abstract: The present disclosure describes oligonucleotide-tethered nucleotides, methods of making them, and methods of using them. The oligonucleotide-tethered nucleotides comprise, in some embodiments, a nucleotide linked to an oligonucleotide of from about 3 to about 100 nucleotides in length. These oligonucleotide-tethered nucleotides can be used to label a plurality of different types of nucleic acids in a plurality of different situations with a known oligonucleotide, which can serve as a barcode in some embodiments. The resulting oligonucleotide-labeled nucleic acids oligo-nucleotides can be used in a variety of nucleic acid sequencing methods.
    Type: Application
    Filed: June 30, 2023
    Publication date: March 28, 2024
    Applicants: Thermo Fisher Scientific Baltics UAB, Life Technologies Corporation
    Inventors: Arvydas Lubys, Inga Cikotiene, Zana Kapustina, Arturas Berezniakovas, Justina Sulgaite, Simona Zeimyte, Mark Andersen, Michael Allen, Sihong Chen
  • Patent number: 11739316
    Abstract: The present disclosure describes oligonucleotide-tethered nucleotides, methods of making them, and methods of using them. The oligonucleotide-tethered nucleotides comprise, in some embodiments, a nucleotide linked to an oligonucleotide of from about 3 to about 100 nucleotides in length. These oligonucleotide-tethered nucleotides can be used to label a plurality of different types of nucleic acids in a plurality of different situations with a known oligonucleotide, which can serve as a barcode in some embodiments. The resulting oligonucleotide-labeled nucleic acids oligonucleotides can be used in a variety of nucleic acid sequencing methods.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: August 29, 2023
    Assignees: Thermo Fisher Scientific Baltics UAB, Life Technologies Corporation
    Inventors: Arvydas Lubys, Inga Cikotiene, Zana Kapustina, Arturas Berezniakovas, Justina Medziune, Simona Zeimyte, Mark Andersen, Michael Allen, Sihong Chen
  • Publication number: 20200399633
    Abstract: The present disclosure describes oligonucleotide-tethered nucleotides, methods of making them, and methods of using them. The oligonucleotide-tethered nucleotides comprise, in some embodiments, a nucleotide linked to an oligonucleotide of from about 3 to about 100 nucleotides in length. These oligonucleotide-tethered nucleotides can be used to label a plurality of different types of nucleic acids in a plurality of different situations with a known oligonucleotide, which can serve as a barcode in some embodiments. The resulting oligonucleotide-labeled nucleic acids oligonucleotides can be used in a variety of nucleic acid sequencing methods.
    Type: Application
    Filed: June 22, 2020
    Publication date: December 24, 2020
    Inventors: Arvydas LUBYS, Inga CIKOTIENE, Zana KAPUSTINA, Arturas BEREZNIAKOVAS, Justina MEDZIUNE, Simona ZEIMYTE, Mark ANDERSEN, Michael ALLEN, Sihong CHEN
  • Patent number: 8314132
    Abstract: Invention is related to novel compounds -5-aryl-4-(5-substituted 2,4-dihydroxyphenyl)-1,2,3-thiadiazoles with general formula (I). The compounds can be used in biomedicine as active ingredients in pharmaceutical formulations, because they inhibit Hsp90 chaperone which participate in cancer progression. This invention is also related to new intermediate compounds which are used for the synthesis of thiadiazoles of general formula (I).
    Type: Grant
    Filed: June 18, 2008
    Date of Patent: November 20, 2012
    Assignee: Biotechnologijos Institutas
    Inventors: Daumantas Matulis, Inga Cikotiene, Egidijus Kazlauskas, Jurgita Matuliene
  • Publication number: 20110046387
    Abstract: Invention is related to novel compounds -5-aryl-4-(5-substituted 2,4-dihydroxyphenyl)-1,2,3-thiadiazoles with general formula (I). The compounds can be used in biomedicine as active ingredients in pharmaceutical formulations, because they inhibit Hsp90 chaperone which participate in cancer progression. This invention is also related to new intermediate compounds which are used for the synthesis of thiadiazoles of general formula (I).
    Type: Application
    Filed: June 18, 2008
    Publication date: February 24, 2011
    Inventors: Daumantas Matulis, Inga Cikotiene, Egidijus Kazlauskas, Jurgita Matuliene